Emerson Electric

Phase A — Understand the business

Lens 1 · Company Overview

Emerson is a ~$18B-revenue global automation company headquartered in St. Louis, incorporated in Missouri in 1890. After a four-year portfolio teardown it is now a focused industrial-technology platform spanning intelligent devices (sensors, valves, actuators) and software & control (control systems + design/optimization software). FY2025 net sales were $18,016M, +3% reported / +3% underlying.

What it sells, in plain terms. When a refinery, chemical plant, LNG train, power station, pharma line or data-center utility plant needs to measure, control and optimize a physical process, Emerson sells the full stack:

• Measurement — Rosemount / Micro Motion / Flexim instruments (pressure, flow, level, temperature, analytical).
• Final control — Fisher / Crosby / Bettis / Keystone control & safety valves and actuators.
• Control systems — DeltaV (process plants) and Ovation (power generation) distributed control systems.
• Software — AspenTech: simulation, asset-performance management, optimization; plus NI/Test & Measurement (modular test, data acquisition).
• Discrete & tools — ASCO/Aventics/Branson (discrete automation), RIDGID/Greenlee (Safety & Productivity).

End markets: process (chemical, power & renewables, energy), hybrid (life sciences, metals & mining, food & beverage), discrete (auto, medical, packaging, semiconductor).

Geography (FY2025 destination): Americas 51%, Asia/ME/Africa 30% (China 10%), Europe 19%; international = 59% of sales incl. US exports.

Contract structure. Mostly point-of-time product sales recognized on shipment, plus a growing recurring base: AspenTech software (term licenses recognized day-one of the contract, plus ratable maintenance) and post-contract support/parts/service. Backlog $8.6B at 9/30/2025 (Intelligent Devices $4.5B, Software & Control $4.1B), ~75% to convert within 12 months — a real visibility cushion, not a take-or-pay structure. R&D + engineering = 8.1% of sales in FY2025 (up from 6.9% in FY2023, reflecting the software shift).

Lens 2 · Supply Chain

Upstream inputs → Emerson → end customer. supply-chain.md for the energy topic is missing, so this is built from the 10-K's raw-materials and distribution disclosures + named brands/customers.

Upstream (inputs Emerson buys): steel, cast iron, electronics/semiconductors, rare-earth metals, aluminum, brass, and to a lesser extent plastics and petroleum-based chemicals. Policy is multi-sourcing — "many sources of supply for each major requirement to avoid significant dependence on any one or a few suppliers". Chokepoints: (1) electronics/chips for instruments and controllers (the same shortage axis that hit the whole sector in 2021-22); (2) rare earths (China-concentrated, a live geopolitical chokepoint for actuators/sensors); (3) tariffs — explicitly flagged as a current margin drag (Section 232/301 + the IEEPA episode, see Lens 5/10).

Manufacturing: ~120 plants worldwide, ~35 in the US and ~85 outside (primarily Europe and Asia). A majority of production is offshore — emerging-market sourcing is a deliberate "best-cost" strategy and a disruption risk the 10-K calls out.

Distribution (Emerson → customer): principal channel is a direct sales force, supplemented by independent sales reps and, to a lesser extent, independent distributors buying for resale. The direct-sales model is a moat input — it keeps Emerson close to the plant engineer and the installed base.

Downstream (who buys): EPC contractors and operators in energy/chemicals (ExxonMobil, Shell, Saudi Aramco-type process owners), power utilities and data-center power plants (the Ovation growth vector), life-sciences manufacturers, and semiconductor/discrete OEMs. customers.csv is empty, so specific concentration is n/a in research layer; the 10-K states no dependence on any single customer and a diversified base — concentration risk is low, the cyclical risk is end-market capex.

Lens 3 · Competitive Advantages (moats)

positioning.md/bottlenecks.md missing — built from the filing + peer web data.

1. Installed base + switching costs (the core moat). A DeltaV or Ovation control system is the brain of a plant; once specified, it is re-validated, re-trained-around and re-spec'd for decades. Rip-and-replace risks unplanned downtime measured in millions/day. This is the durable franchise — high-margin aftermarket (parts, service, upgrades) rides on a sticky base. Software & Control adjusted EBITA margin reached 31.0% in FY2025 (up 4.0 pts) on exactly this dynamic.
2. Brand/spec breadth. Fisher, Rosemount, Micro Motion, Crosby — category-defining brands an operator writes into a spec sheet by name. Pricing power shows up as +2.5% price in FY2025 underlying growth with volume only +0.5%, and +3.5% price in Q2-FY2026.
3. Software flywheel (AspenTech). Owning AspenTech outright lets Emerson fuse the optimization layer (the math) with the control layer (the hardware) and the measurement layer (the data) — a stack rivals can't fully assemble. This is the "software-defined automation" thesis and the AI-optimization angle.
4. Bargaining power. Over suppliers: moderate-high — multi-sourced commodities, scale buyer. Over customers: high on installed-base aftermarket, moderate on new greenfield projects (competitive bids vs Honeywell/Siemens/ABB). Net: Emerson needs the capex cycle more than any single customer needs Emerson, but within a running plant the operator needs Emerson more.

Honest moat check: the moat is real but narrower in scope post-transformation — Emerson is now levered to industrial/process capex with less consumer/commercial ballast, so the franchise is higher-quality but more cyclically exposed (the 10-K concedes "a narrower business... may encounter more volatility").

Lens 4 · Segments

segments.csv is empty; all figures below are ``. Note a mid-year reorganization: the FY2025 10-K reports six segments in two groups; the Q2-FY2026 10-Q reports a regrouped structure — Software & Systems (Control Systems & Software + Test & Measurement) and Sensors + Final Control under Intelligent Devices, plus Safety & Productivity. Both are reconciled below.

FY2025 by segment (10-K basis), sales / segment EBIT / adj. EBITA margin:

Trend & cause:

• Software & Control is the engine. Segment EBIT exploded +193% to $827M (margin 5.2% → 14.5%) as the NI inventory step-up/backlog amortization rolled off and AspenTech contract-renewal timing landed favorably; adj. EBITA margin 31.0%. This is decelerating-amortization optics plus genuine operating leverage.
• Final Control accelerating (+4%, "strength in power end markets") — the cleanest read on the data-center/power capex tailwind.
• Discrete Automation & Safety/Productivity are the soft spots (+1% / −2%) — short-cycle, exposed to weak European and factory-automation demand.
• Test & Measurement (NI) still loss-making at the segment-EBIT line in FY2025 (−$68M) but improving sharply from −$290M as cost actions bite; adj. EBITA basis is profitable. The NI integration is the open margin story.

Geography (Q2-FY26, six months): Americas $4,570M, AMEA $2,568M, Europe $1,770M — Americas is carrying growth (US +9% underlying in Q2), Europe and China are a drag (China −9% in Q2).

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print: Q2 FY2026, quarter ended 3/31/2026)

The latest filing on the shelf is the 10-Q for the quarter ended March 31, 2026 (fiscal Q2 2026), filed 2026-05-05.

Headline:

• Net sales $4,562M, +3% reported but +0.5% underlying — a soft top line. Mix: +3.5% price, −3% volume, of which −2% from software-renewal timing and −1% from the Middle East conflict; FX +2.5%.
• GAAP diluted EPS $1.10 (+28%); adjusted diluted EPS $1.54 (+4%) vs $1.48, despite a −$0.09 software-renewal-timing hit.
• Gross margin 53.1% (−0.4 pt) — tariffs + renewal timing diluted by ~0.8 pt, mostly offset by price.
• Pretax margin 17.4% (+3.2 pts), flattered by the prior-year AspenTech deal costs dropping out.
• Effective tax rate 22% (vs 32% PY); OBBBA added ~1 pt, offset by favorable items.

vs consensus. Web: the Street had Q2 EPS ~$1.41 forecast; the company "beat EPS, revenue miss". Q1 FY26 (Dec-2025 quarter) was a cleaner beat-and-raise — adj. EPS $1.46 vs $1.41 est, guidance raised. So the two-quarter pattern is: earnings/orders beating, revenue softer than hoped, guidance creeping up.

Drivers. Software & Systems +4%, Intelligent Devices +2%, Safety & Productivity +5%. The standout is orders: underlying orders +9% in Q1 FY26, fourth consecutive strong quarter, with Ovation power-control orders +74% including automating a 1.7 GW AI data center. Management framed FY26 as growth ramping from LSD in H1 to LDD by year-end on order momentum.

Balance-sheet flags. Operating working capital rose to $2,610M (Mar-26) from $2,039M (Sep-25) on higher inventory + lower accruals. 6-month FCF $1,296M, down $137M YoY on the working-capital build. Interest coverage fell to 7.5x (from 9.8x) on AspenTech-deal debt.

Raised guidance (at the half): FY26 sales +~4.5% (underlying +~3%), GAAP EPS $4.79–4.89, adjusted EPS $6.45–6.55 (up from the FY-end guide of $6.35–6.55), OCF $4.0–4.1B, FCF $3.5–3.6B, $2.2B returned to holders ($1.0B buyback + ~$1.2B dividends).

Unusual vs own history: the underlying-sales softness (+0.5%) is the lowest in several quarters and entirely explained by two one-offs (renewal timing reverses; Middle East is exogenous). The quality signal — orders and raised EPS — points the other way. The stock has run hard regardless: +26% one-year TSR, +~36% over the trailing year per separate reads.

Lens 6 · Earnings Calls (sentiment trend)

transcripts/ is empty — no transcripts on the shelf. Sentiment is reconstructed from filings (MD&A tone) + web transcript summaries; label /.

• Recurring themes management leans on: "software-defined automation," portfolio transformation "complete," order momentum (the most-repeated proof point), power & LNG & AI data centers as the demand drivers, and AspenTech synergy delivery ($100M cost synergies by 2028; broader $200M cost+revenue synergies by 2027).
• Tone shift over the last ~4 prints: FY2025 = "transformation done, now operate"; Q1 FY26 = confident beat-and-raise, leaning into data-center/power; Q2 FY26 = slightly more defensive — acknowledging Middle East drag, tariff dilution, software-renewal timing, but reaffirming the H2 ramp. Net: constructive but increasingly reliant on the back-half ramp — a "trust the orders" posture.
• What they stopped saying: the divestiture/"reshaping the portfolio" narrative has receded (it's executed); the message is now organic growth + software mix + capital return.

Caveat: with no primary transcripts ingested, sentiment confidence is medium. A refresh should ingest the last 4–6 quarters from Motley Fool / Insider Monkey.

Lens 7 · Comps

Peer set: the global process/factory-automation majors. _index.json had no usable energy-topic peers for this slug, so peers are the obvious names. **Multiples are with date; where a figure isn't cleanly sourced it is `n/a`.** EMR financials are.

Reads:

1. EMR is the cheapest of the automation pure-plays on EV/EBITDA (~15-16x) and forward P/E (~22x) — cheaper than ROK (~45x fwd) and Schneider (~18x EV/EBITDA). On its own franchise quality that looks attractive.
2. But EMR's ROE (~12%) is roughly a third of Honeywell's (~33%) and half of Rockwell's (~24%). The discount is earned: the transformation loaded the balance sheet with $18.2B goodwill + $9.5B intangibles = $27.7B of a $42B asset base, depressing returns on equity/capital (ROIC ~10.9% ). The lower multiple is partly a lower-quality-of-capital signal, not a free lunch.
3. vs its own history: EMR fwd P/E ~22x sits at/above its 5-yr average ~19-19.4x; trailing P/E ~33x is well above the 5-yr median ~22x. The re-rating to a secular-growth multiple has already happened.

Lens 8 · Stock-Price Catalysts (what moves EMR >5%)

Mostly ``, pattern-read across the cycle.

• Portfolio events (2022-2025) were the dominant re-rating driver. InSinkErator sale to Whirlpool ($3.0B, FY2023), the Copeland/Climate sale to Blackstone ($14.0B, 2023), the NI acquisition ($8.2B, Oct-2023), and the AspenTech minority buyout ($265/sh, ~$17B EV, closed Mar-2025). The market rewarded the pivot to a higher-multiple software/automation pure-play.
• Orders > revenue as the reaction trigger now. In FY26 the stock has reacted to order growth and data-center wins (Ovation +74%, the 1.7 GW AI-data-center automation) more than to the soft revenue line — Q1 FY26 beat-and-raise sent it up; the Q2 "EPS beat / revenue miss" was digested without a blow-up.
• Analyst upgrades: Jefferies → Buy, target $175 (from $160) in Mar-2026 — the "AI-power beneficiary" re-rating thesis in one data point.
• Historical activist catalyst: D.E. Shaw pushed for a breakup in 2019 (the "8 airplanes" waste critique); Emerson declined to split. No current confirmed activist campaign (Third Point/Loeb) on EMR as of this run — searches surfaced only the historic D.E. Shaw episode and Elliott's involvement on the AspenTech side. Label: not active.
• Macro/cyclical: EMR moves with the industrial/process-capex cycle, oil & gas & power capex, China demand, FX, and tariffs. It is a high-beta-to-capex, dividend-defensive hybrid.

What the tape says the market actually reacts to: (1) M&A/portfolio strategy, (2) order trajectory and the AI-power narrative, (3) margin/EPS guidance revisions. Pure revenue prints matter least.

---

Phase C — Judge people & books

Lens 9 · Management

CEO — Surendralal "Lal" Karsanbhai (56). Emerson lifer (joined 1995); CEO since Feb 2021, President since Mar 2021; prior EVP-Automation Solutions.

1. Track record (quantified): executed "the most dramatic portfolio transformation in Emerson's 130-year history" — shed >$17B of consumer/commercial assets (InSinkErator $3B, Copeland $14B) and redeployed into automation/software (NI $8.2B, AspenTech). Result: a higher-margin mix — company adjusted EBITA margin 23.4% → 26.0% FY23→FY25, gross margin 49.0% → 52.8%. He delivered the margin/mix story he promised.
2. Tenure & skin in the game: ~5 yrs as CEO. Insider ownership ~1.8% of shares; institutions ~81-83% (Vanguard ~9.7%, BlackRock ~7.5% the largest holders). Founder-level alignment: no — this is a professional-manager, widely-held mega-cap.
3. Capital allocation: the defining record. Reinvest: R&D up to 8.1% of sales. Acquire: aggressive, software-tilted (NI, AspenTech) — the AspenTech minority squeeze-out is the contested one (see Lens 13). Buy back: $1,167M FY25 (9.3M sh @ $125.66 avg), new 50M-share authorization Nov-2025. Dividend: Dividend King — 68+ consecutive years of increases; raised to $2.22 annualized Nov-2025. The honest scorecard: excellent on shareholder return and mix; the jury is out on whether $17B+ of M&A earns its cost of capital — ROIC ~10.9% and ROE ~12% are below peers, i.e. the capital deployed hasn't yet generated peer-level returns.
4. Red flags: the AspenTech buyout governance — Emerson, as ~57% controlling holder, took out the minority at a price its largest minority (Elliott, >$1.5B) called "highly opportunistic"; Elliott sued in Delaware for merger records. A controlling-shareholder squeeze-out is a textbook conflict; the deal closed at $265 (raised from the initial $240 proposal) with a majority-of-minority condition. Worth holding against the "great capital allocator" narrative.
5. Archetype: disciplined professional operator / portfolio surgeon — the right profile for this phase (integrate, optimize, return cash), less obviously the profile for the next phase (organic, software-led reacceleration). CFO Michael Baughman (ex-Baxter) and COO Ram Krishnan round out a long-tenured Automation-Solutions bench.

Lens 10 · Forensic Red Flags

Forensic-analyst posture. Every figure labeled.

• Goodwill & intangibles dominate the balance sheet. $18.2B goodwill + $9.5B other intangibles = 66% of $42B total assets; common equity is only $20.3B — i.e. tangible equity is deeply negative. The whole thesis rides on the acquired franchises (NI, AspenTech) not impairing. Goodwill tested annually in Q4; no impairment taken. This is the single largest accounting risk — an NI/Test & Measurement stumble (still segment-EBIT-negative in FY25) could trigger a write-down.
• GAAP vs adjusted gap is wide and amortization-driven. FY25 GAAP cont-ops EPS $4.03 vs adjusted $6.00 — a $1.97 (49%) bridge, of which $1.35 is intangibles amortization. That amortization is a real echo of cash already spent on M&A; treat adjusted EPS with that lens. SBC is modest and consistent (~$263M FY25, ~$0.46/sh equiv) — not an aggressive non-GAAP flatterer here.
• FY2023 net income optics. FY2023 net EPS of $22.88 is a one-time artifact of the $8.4B after-tax Copeland gain + $2.1B InSinkErator gain in discontinued ops — not operating earnings. Any model anchoring on FY23 GAAP net income is wrong; continuing-ops is the right base.
• Cash flow vs earnings: healthy — FY25 OCF $3.7B on $2.25B net earnings; D&A ($1.5B) and the amortization add-back explain the gap. FCF $3.2B, 18% of sales. No divergence red flag. The Q2-FY26 working-capital build (inventory up) is worth monitoring but is small.
• Leverage stepped up for AspenTech: total debt $13.1B at 9/30/25 (from $7.7B), total-debt-to-capital 39.3% (from 26.2%), but interest coverage still 8.6x and management commits to deleveraging while retaining investment-grade ratings. Manageable, not alarming.
• Pension: US plans overfunded by $856M (~29% above PBO) — a positive, with surplus funding a new cash-balance program; non-US underfunded $65M. No pension hole.
• Tariff/IEEPA timing item: in Feb-2026 the US Supreme Court ruled IEEPA didn't authorize certain tariffs; CBP opened a refund portal Apr-2026, but Emerson booked no refund benefit as of 3/31/26 (conservative) — a small potential upside, not a risk.

Regulatory findings (required sub-section).

• SEC Litigation Releases / AAERs: none. regulatory/regulatory-findings.md (generated 2026-06-30 via SEC EDGAR EFTS, LR+AAER, period 2021-06-30→2026-06-30) returned 0 SEC findings for Emerson Electric.
• 10-K Item 3 (Legal Proceedings): Emerson discloses it is "party to various legal proceedings, some of which claim substantial amounts of damages," but states a material adverse impact is "unlikely"; details in Note 15. Includes a long-tail asbestos reserve projected through 2065 (recorded undiscounted) — standard for a 130-yr-old industrial, actuarially estimated, with insurance receivables. No single material case named.
• Non-SEC enforcement (web): no material FTC/DOJ/FDA/CFPB enforcement action or consent decree surfaced. The most material governance matter is civil/private, not regulatory: Elliott's Delaware books-and-records suit over the AspenTech merger process — a fiduciary/conflict dispute, not an agency action.
• Verdict: No material regulatory or accounting-enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-30. The watch-item is the controlling-shareholder governance precedent set by the AspenTech squeeze-out, plus the goodwill-impairment exposure.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (FY2026 → FY2028, adjusted continuing-ops EPS)

Built bottom-up from company guidance + actuals. Output ``; inputs labeled. No forecast.ts create run (watchlist breadth mode — forecast logging is skipped per skill rules).

Anchors:

• FY2025 actual adjusted EPS $6.00.
• FY2026 company guidance adjusted EPS $6.45–6.55 (midpoint $6.50), sales +~4.5% / underlying +~3%.
• Street: FY26 ~$6.51, FY27 ~$7.13–7.18.

The base case is essentially the consensus path: ~$6.50 → ~$7.10 → ~$7.75, ~9%/yr adjusted-EPS growth. At today's ~$143 that's ~22x FY26 / ~20x FY27 / ~18.5x FY28. For reference, a Brier-scoreable base call would be "EMR FY26 (ending 9/30/2026) adjusted EPS ≥ $6.45," p≈0.80 — high probability given the half is banked and guidance was raised; not logged this run.

Lens 12 · Bull vs Bear

Bull case. Emerson is a completed transformation now sitting in the sweet spot of the AI-power / electrification / LNG capex supercycle. The cleanest pure-play on automating the physical buildout: Ovation orders +74% with a 1.7 GW AI-data-center win; Final Control "strength in power"; AspenTech adds a software-optimization flywheel with $200M synergies by 2027. Margins are still climbing (Software & Systems 31% adj. EBITA and rising as NI losses fade), the dividend is a 68-year King, FCF is ~$3.5B and ~$2.2B/yr comes back to holders. Earnings surprise vector: the H2-FY26 ramp from LSD to LDD growth, plus NI flipping to segment profit, plus a possible IEEPA tariff refund. On ~22x forward for a re-accelerating, sticky-installed-base compounder, bulls argue the quality justifies the multiple — and it's cheaper than ROK.

Bear case (2–3 permanent-impairment / de-rating risks).

1. The re-rating already happened — multiple risk. ~33x trailing / ~22x forward vs a 5-yr median ~22x trailing / ~19x forward. The stock is priced as a secular grower; if growth proves merely cyclical, the multiple compresses and earnings disappoint — a double-hit. GuruFocus pegs intrinsic value ~$129 vs ~$143 (≈11% over).
2. It's still a capex-cyclical wearing a software costume. Underlying sales were +0.5% last quarter; the "growth" is order-book and narrative. If the AI-data-center power order surge is a pull-forward, or oil & gas / China / European factory capex rolls, the order book deflates and the back-half ramp doesn't show.
3. Capital-quality drag. $27.7B goodwill+intangibles, ROE ~12%, ROIC ~11% — structurally below peers. If NI/Test & Measurement keeps underperforming, a goodwill write-down is a real tail risk, and the "great M&A" story inverts.

Pre-mortem (18 months out, thesis broke): orders normalized after a 2025-26 data-center pull-forward; underlying growth slipped back to ~2%; the H2-FY26 LDD ramp never materialized; a soft guide in late FY26 collided with a 22x multiple → the stock de-rated to ~17x ($120s). Tariffs/FX and China stayed a drag; NI took a goodwill charge.

Are multiples too high? For the cycle position, modestly yes — EMR is priced for secular reacceleration it has not yet demonstrated in the revenue line. Not bubble-like (it's the cheapest pure-play), but little margin of safety at ~$143.

Contrarian view (what the market is refusing to see): the bull crowd treats EMR as an "AI-power infrastructure" stock, but the AspenTech software-optimization flywheel — owning the math + the controls + the data on a sticky installed base — may be a bigger, more durable margin story than the cyclical data-center order pop everyone is fixated on. The market is paying for the cyclical catalyst and under-appreciating the structural software mix-shift. Conversely, the market may be under-pricing the governance discount the AspenTech squeeze-out deserves.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• What structurally breaks the money machine: Emerson sells into lumpy industrial/energy capex. Strip the narrative and Q2 underlying growth was +0.5%. The entire bull thesis leans on orders (+9%) converting and not being a 2025-26 AI-data-center pull-forward. If hyperscaler power-buildout orders are front-loaded, 2027 faces an air pocket against a 22x multiple.
• Concentration risk: less single-customer than geographic/end-market — heavy on energy/process/power capex and on the Americas (carrying all the growth while Europe −4% and China −9% in Q2). A US-capex or oil-price wobble hits disproportionately.
• Why the moat may be weaker than bulls think: Honeywell, Siemens, ABB and Schneider all sell competing process-automation stacks and out-earn Emerson on ROE (HON ~33%, ROK ~24% vs EMR ~12% ). On new greenfield projects it's a competitive bid; the moat is the installed base, not new wins.
• Most dangerous competitor bulls underestimate: Schneider Electric — broader electrification + data-center power footprint, comparable software ambition, and a market that already pays it ~18x EV/EBITDA. In the electrification/data-center-power narrative Emerson is selling, Schneider is arguably better-positioned.
• Worst capital-allocation move: the AspenTech minority squeeze-out — a controlling holder taking out minorities at a price the largest minority called "opportunistic," drawing a Delaware suit. Combined with paying $8.2B for NI (still segment-EBIT-negative two years on), the M&A record is "transformative" but return-dilutive so far (ROIC ~11%).
• Assumptions that must hold for ~$143: (1) underlying growth reaccelerates to ~5%+ and stays; (2) AspenTech synergies + NI turnaround land; (3) margins keep climbing; (4) the ~22x multiple holds. If growth disappoints by 20-30% (underlying ~2% instead of ~5%, FY27 EPS ~$6.6 vs ~$7.1) and the multiple slips to ~18x, you get ~$120 — roughly −16%.
• Single scenario that permanently impairs: a hard global industrial-capex recession that idles process/energy projects and forces an NI/Test & Measurement goodwill write-down — hitting both earnings and the balance-sheet equity at once. Plausibility: low-to-moderate (cycle-dependent), but it's the real tail.

Lens 14 · Management Questions (ordered by information value)

1. Of the FY26 underlying-order strength, how much is AI-data-center / power demand, and how much of that is a one-time buildout pull-forward vs a durable multi-year run-rate? (The whole thesis hinges here.)
2. Two years in, when does Test & Measurement (NI) reach segment-EBIT breakeven and its target margin — and at what point would you consider impairing the goodwill if it doesn't?
3. On the AspenTech buyout at $265: how do you answer Elliott's claim the price was opportunistic, and what return on the ~$17B EV do you underwrite — at what ROIC and by when?
4. ROE/ROIC are ~12%/~11%, well below Honeywell and Rockwell. What is your explicit target and timeline to close that gap, and is it achievable without another transformation?
5. What underlying-growth rate does the business model deliver through a full cycle, stripping FX, price and one-offs — is the through-cycle number 3% or 5%+?
6. How much of recent growth is price (+3.5% in Q2) vs volume (−3%), and how durable is that pricing as tariffs and input costs normalize?
7. What is the net tariff exposure after Section 232/301 and the IEEPA refund, and what's the annualized EPS sensitivity?
8. What's the organic R&D-to-revenue ROI — what share of growth comes from new products vs the installed-base aftermarket?
9. Capital allocation priority for the next $5B of FCF: deleveraging, buyback, dividend, or more software M&A — and what's the hurdle rate?
10. How defensible is the AspenTech software franchise against cloud/AI-native optimization entrants, and what's the renewal/retention rate?
11. What is the realistic China trajectory (−9% in Q2) and how structurally exposed is the model to a prolonged China industrial slowdown?
12. How do you think about the goodwill+intangibles at 66% of assets / negative tangible equity as a financial-resilience constraint in a downturn?
13. What would make you break the company up (the recurring activist ask), and why is the current structure worth more together?
14. How much margin runway is left in Software & Systems beyond the current 31% adj. EBITA, and what's the ceiling?
15. What's the succession and bench plan, and how is management comp tied to ROIC/organic growth vs total-shareholder-return optics?

---